Subsequent-generation antibody-based platform redirects endogenous cytokines to deal with cancers and autoimmune ailments
Confirmed staff with deep drug growth expertise
VANCOUVER, British Columbia–(BUSINESS WIRE)– Reverb Therapeutics, a frontrunner within the rising paradigm of redirecting endogenous cytokines as therapies for life-threatening ailments, debuts with seed financing led by founding investor Amplitude Ventures and participation from the A number of Myeloma Analysis Basis’s enterprise philanthropy arm, the Myeloma Funding Fund.
AmplifierTM Platform for redirecting cytokines
Reverb Therapeutics is advancing its novel antibody-based AmplifierTM platform to deal with a broad vary of ailments with endogenous cytokines that naturally happen inside the physique. As a substitute of utilizing closely engineered exogenous cytokines to deal with illness—which have constantly introduced challenges corresponding to systemic toxicity, immunogenicity and difficult manufacturing necessities—Reverb’s antibodies redirect endogenous, pure cytokines to cells of curiosity. This method avoids the systemic publicity and threat of immunogenicity seen with most exogenous cytokine therapies. The corporate plans to make use of the present seed spherical to carry two packages to the candidate stage. Reverb’s lead pipeline packages harness IL-15 to activate particular immune cells and to focus on a broad number of cancers.
“We’re keenly conscious of the scientific obstacles to extra widespread use of exogenous cytokines to deal with sufferers,” stated David de Graaf, Ph.D., Co-founder and CEO of Reverb Therapeutics. “Reverb’s proprietary Amplifier antibodies make the most of customary IgG frameworks together with superior computational modeling and antibody engineering to construct first-in-class novel therapeutics. The platform is designed to be modular and to make use of parts of present and novel antibodies to redirect a given cytokine to a selected tumor, tissue or immune cell. It’s broadly relevant throughout stable and liquid tumors and auto-immune ailments.”
“We’re excited by the potential of Reverb’s Amplifier platform for the remedy of a number of myeloma,” stated Michael Andreini, President and CEO on the MMRF. “The rising preclinical knowledge counsel that this extremely differentiated platform method to cytokine remedy may very well be promising for myeloma sufferers.”
“There’s loads of exercise within the cytokine area,” stated Bharat Srinivasa, Principal at Amplitude and co-founder of Reverb. “Reverb’s proprietary Amplifier platform stands out. It’s elegant and simple, uniquely able to utilizing endogenous cytokine biology to create medication with elevated efficacy.” Amplitude Ventures co-founded Reverb by means of its Pre-Amp enterprise studio program. As a part of the financing, Bharat Srinivasa and Ali Tehrani, Associate at Amplitude, have joined Reverb’s board of administrators.
Founding staff and SAB
Reverb is based and led by a staff of seasoned executives with many years of expertise in discovering and creating biologics. The staff is chargeable for greater than 12 late-stage scientific packages and two marketed merchandise. The staff consists of:
- David de Graaf, co-founder, president and CEO is a serial biopharma entrepreneur, having co-founded and led greater than 5 firms in his profession from founding to late-stage scientific growth. His experiences embrace being CEO at Abcuro, Comet (acquired by VectivBio) and Syntimmune (acquired by Alexion) and management roles at Apple Tree Companions, Flagship Pioneering, Pfizer, AstraZeneca and Boehringer Ingelheim.
- Surjit Dixit, Co-founder, CSO is an skilled science chief, and was Chief Expertise Officer at Zymeworks the place he conceived and directed growth of the agency’s greatest in school Azymetric™ bispecific platform, which has generated a number of pharma partnerships and Zanidatamab, the main biparatopic antibody being evaluated in registrational scientific trials.
The corporate can also be supported by an impressive scientific advisory board. The SAB consists of:
Peter Sorger, D. Phil., Head of Therapeutic Sciences and Professor of Techniques Biology at Harvard College;
Fred D. Finkelman, M.D., Professor of Drugs on the College of Cincinnati Faculty of Drugs
Peter Zandstra, Ph.D., Founding Director of the College of Biomedical Engineering, College of British Columbia;
John Burke, Ph.D., founder and CEO of Utilized Biomath.
About Reverb Therapeutics
Based mostly in Vancouver, Reverb Therapeutics is the chief within the growth of therapies for most cancers and different ailments utilizing the physique’s pure endogenous cytokines. Reverb’s Amplifier™ Antibody platform avoids the systemic toxicity usually related to cytokine therapies by rising cytokine ranges solely in focused tissues. Components of Amplifier antibodies are reusable, permitting Reverb to quickly scale its pipeline throughout a number of illness areas. Be taught extra about alternatives to work with Reverb by contacting data@reverbtx.com
About Amplitude Ventures
Amplitude is a full-stack enterprise capital agency utilizing a novel development mannequin to construct firms with world-class administration groups and scale firms to breakout potential. With over $500 million underneath administration and places of work in Montreal, Toronto and Vancouver, Amplitude applies a confirmed, evidence-based method to investing in main precision medication firms. Be taught extra about Amplitude and its Pre-Amp enterprise studio at amplitudevc.com.
Concerning the Myeloma Funding Fund
The Myeloma Funding Fund is a enterprise philanthropy fund that invests in promising firms, scientific property, and applied sciences in oncology to drive the event of recent therapies for a number of myeloma. The MIF collaborates carefully with portfolio firms to assist them advance a number of myeloma analysis. This evergreen fund is supported solely by philanthropy; all income might be reinvested again into analysis for more practical therapies till there’s a remedy for each affected person. For extra info, go to www.myelomainvestmentfund.org.
View supply model on businesswire.com: https://www.businesswire.com/information/residence/20231115635574/en/
